Growth Metrics

Castle Biosciences (CSTL) Cash from Investing Activities (2018 - 2025)

Castle Biosciences (CSTL) has disclosed Cash from Investing Activities for 8 consecutive years, with $8.8 million as the latest value for Q4 2025.

  • Quarterly Cash from Investing Activities rose 53.05% to $8.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$60.4 million through Dec 2025, down 20.4% year-over-year, with the annual reading at -$60.4 million for FY2025, 20.4% down from the prior year.
  • Cash from Investing Activities hit $8.8 million in Q4 2025 for Castle Biosciences, up from -$18.4 million in the prior quarter.
  • In the past five years, Cash from Investing Activities ranged from a high of $16.6 million in Q1 2023 to a low of -$134.2 million in Q3 2022.
  • Historically, Cash from Investing Activities has averaged -$18.0 million across 5 years, with a median of -$15.1 million in 2023.
  • Biggest five-year swings in Cash from Investing Activities: plummeted 14434.13% in 2022 and later soared 4225.37% in 2023.
  • Year by year, Cash from Investing Activities stood at -$30.9 million in 2021, then soared by 85.49% to -$4.5 million in 2022, then crashed by 71.17% to -$7.7 million in 2023, then soared by 175.21% to $5.8 million in 2024, then skyrocketed by 53.05% to $8.8 million in 2025.
  • Business Quant data shows Cash from Investing Activities for CSTL at $8.8 million in Q4 2025, -$18.4 million in Q3 2025, and -$28.4 million in Q2 2025.